Sequence information


DRAVP ID  DRAVPc001

Name   Brilacidin

Sequence  Not available

Molecular Formula  C40H50F6N14O6

Condition/Disease  COVID-19

Group  Phase Ⅱ clinical trial

Type  small molecule mimetic of defensin

Description  Brilacidin is a synthetic, nonpeptidic, small molecule mimetic of defensin, a type of host defense proteins/peptides (HDPs) or antimicrobial peptides (AMPs), with potential antibacterial and antiviral activities. Upon administration, brilacidin selectively destabilizes bacterial and viral membrane integrity, which leads to their proteolysis and degradation. HDPs are part of the innate immune response and act as the first line of defense against foreign pathogens. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection has been shown to suppress defensins.

Active sequence/Structure 


External Links


DrugBank Accession Number  DB12997

Pubchem ID  25023695

CHEMBL ID  CHEMBL2219413

UNII  I1679X069H

CAS  1224095-98-0

Reference  35080027  35695877  33572467 



ClinicalTrails Information


NCT Number Study Title Condition/Disease Status Phase Sponsor
NCT04784897 A Study to Evaluate the Efficacy and Safety of Brilacidin in Hospitalized Participants With COVID-19 COVID-19 Completed Phase 2 Innovation Pharmaceuticals, Inc.